



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FERRARA ET AL. Examiner: P. HUYNH  
Serial No.: 10/692,299 Group Art Unit: 1644  
Filed: OCTOBER 22, 2003 Docket: 11669.139USC1  
Confirmation No.: 9503  
Title: EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE

**CERTIFICATE UNDER 37 CFR 1.8:**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on February 16, 2006.

By: Kristine A. Wacek  
Name: Kristine A. Wacek

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**23552**  
PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- Transmittal Sheet in duplicate containing Certificate of Mailing
- Supplemental Information Disclosure Statement, Form 1449, 22 Reference(s)
- Check(s) in the amount of \$180.00 for filing Supplemental IDS after receipt of Office Action
- Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.  
P.O. Box 2903  
Minneapolis, MN 55402-0903  
612.332.5300

By: E. DeMaster  
Name: Eric E. DeMaster  
Reg. No.: 55,107  
EDeMaster:PLSkaw



FEB 21 2006

S/N 10/692,299

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	FERRARA ET AL.	Examiner:	P. HUYNH
Serial No.:	10/692,299	Group Art Unit:	1644
Filed:	OCTOBER 22, 2003	Docket No.:	11669.139USC1
Title:	EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on February 16, 2006.

By:   
Name: Kristine A. Wacek

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

23552  
PATENT TRADEMARK OFFICE

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300


Date: February 16, 2006

  
Eric E. DeMaster  
Reg. No. 55,107  
EED:PLSkaw

Date Mailed: FEBRUARY 16, 2006

Sheet 1 of 2

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> <small>(Use several sheets if necessary)</small>		Docket Number: 11669.139USC1	Application Number: 10/692,299
		Applicant: FERRARA ET AL.	
		Filing Date: 10/22/2003	Group Art Unit: 1644



## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 834 563 A2	04/08/1998	EP				
	1 033 401 A2	09/06/2000	EP				
	0 607 054 B1	11/20/2002	EP				
	WO 97/07198	02/27/1997	PCT				
	WO 98/39448	09/11/1998	PCT				
	WO 98/42741	10/01/1998	PCT				
	WO 99/46375	09/16/1999	PCT			Abstract	
	WO 99/53040	10/21/1999	PCT			Abstract	
	WO 99/63083	12/09/1999	PCT			Abstract	
	WO 00/08145	02/17/2000	PCT				
	WO 01/57190 A2	08/09/2001	PCT				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)		Docket Number: 11669.139USC1	Application Number: 10/692,299
		Applicant: FERRARA ET AL.	
		Filing Date: 10/22/2003	Group Art Unit: 1644

<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)		
		NCBI, Accession Number: AF131820; Direct Submission, Submitted: February 26, 1999, Mei, G. et al.
		NCBI, Accession Number: AA865629; National Cancer Institute, 1997, Strausberg, Robert
		NCBI, Accession Number: AA150370; Genome Research, 1996, Hillier, L. et al.
		NCBI, Accession Number: AA843667, National Cancer Institute, 1997, Strausberg, Robert
		Brandon, C., "Improved Immunocytochemical Straining Through the Use of Fab Fragments of Primary Antibody, Fab-specific Second Antibody, and Fab-Horseradish Peroxidase," <i>Journal of Histochemistry and Cytochemistry</i> , Vol. 33, No. 7, pp. 715-719 (1985)
		Klein, R. et al., "Selection for Genes Encoding Secreted Proteins and Receptors," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 7108-7113 (July 1996)
		Schnabel, M. et al., "Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture," <i>Osteoarthritis and Cartilage</i> , Vol. 10, pp. 62-70 (2002)
		Tashiro, K. et al., "Signal Sequence Trap: A Cloning Strategy for Secreted Proteins and Type I Membrane Proteins," <i>Science</i> , Vol. 261, pp. 600-603 (July 30, 1993)
		Wallin, E. et al., "Properties of N-terminal tails in G-protein coupled receptors: a statistical study," <i>Protein Engineering</i> , Vol. 8, No. 7, pp. 693-698 (1995)
		Yokoyama-Kobayashi, M. et al., "A signal sequence detection system using secreted protease activity as an indicator," <i>Gene</i> , Vol. 163, pp. 193-196 (1995)
		Zhang, Y. et al., "Versican Modulates Embryonic Chondrocyte Morphology via the Epidermal Growth Factor-like Motifs in G3," <i>Experimental Cell Research</i> , Vol. 263, pp. 33-42 (2001)



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	